Format

Send to

Choose Destination
Mayo Clin Proc. 2015 Aug;90(8):1054-81. doi: 10.1016/j.mayocp.2015.06.009.

Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement.

Author information

1
Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address: dispenzieri.angela@mayo.edu.
2
Division of Hematology, Mayo Clinic, Rochester, MN.
3
Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ.
4
Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.
5
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.

Abstract

Immunoglobulin light chain amyloidosis (AL amyloidosis) has an incidence of approximately 1 case per 100,000 person-years in Western countries. The rarity of the condition not only poses a challenge for making a prompt diagnosis but also makes evidenced decision making about treatment even more challenging. Physicians caring for patients with AL amyloidosis have been borrowing and customizing the therapies used for patients with multiple myeloma with varying degrees of success. One of the biggest failings in the science of the treatment of AL amyloidosis is the paucity of prospective trials, especially phase 3 trials. Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion.

PMID:
26250727
DOI:
10.1016/j.mayocp.2015.06.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center